SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Class Action Against C3.ai, Inc.
SAN DIEGO–(BUSINESS WIRE)–$AI #IPO—The Class: Shareholder rights law firm Robbins LLP reminds investors that a…
SAN DIEGO–(BUSINESS WIRE)–$AI #IPO—The Class: Shareholder rights law firm Robbins LLP reminds investors that a…
NEW YORK–(BUSINESS WIRE)–#C3–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces…
Campaign asks public to increase water saving as state enters third year of drought LOS…
LAFAYETTE, La.–(BUSINESS WIRE)–SchoolMint®, the leading provider of Strategic Enrollment Management and positive behavior products for…
Irreversible covalent menin inhibitor, BMF-219, exhibited high potency and complete growth inhibition in high-grade B-cell…
Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m….
Poster presentations to highlight data from ongoing studies of the company’s lead Pan-RAF kinase inhibitor…
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral…
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) — 7 Hills Pharma LLC (“7 Hills” or “7HP”),…
Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual…
– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition – SAN DIEGO, March 08,…
– New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that…
— Oral presentation to discuss how translational immunology data…
CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT),…
Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative…
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology…
Continues to interact with FDA regarding orphan drug review of the NDA for Libervant™ (diazepam)…
Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and…
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company…
LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors…